Proteonomix Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2008
2009
2010
2011
Sales/Revenue
132.00
141.60
83.30
26.00
Cost of Goods Sold (COGS) incl. D&A
381.90
615.90
834.80
634.70
Gross Income
249.90
474.30
751.50
608.70
SG&A Expense
4,606.10
3,344.50
2,698.60
698.40
EBIT
4,856.00
3,818.70
3,450.10
1,307.10
Unusual Expense
96.30
-
-
-
Interest Expense
209.70
39.30
19.00
76.60
Pretax Income
4,969.40
3,858.00
3,469.10
1,383.80
Income Tax
-
-
0.90
0.10
Consolidated Net Income
4,969.40
3,858.00
3,470.00
1,383.80
Net Income
4,969.40
3,858.00
3,470.00
1,383.80
Net Income After Extraordinaries
4,969.40
3,858.00
3,470.00
1,383.80
Net Income Available to Common
4,969.40
3,858.00
3,470.00
1,383.80
EPS (Basic)
2.33
1.16
0.75
0.21
Basic Shares Outstanding
2,131.00
3,325.30
4,629.90
6,545.20
EPS (Diluted)
2.33
1.16
0.75
0.21
Diluted Shares Outstanding
2,131.00
3,325.30
4,629.90
6,545.20
EBITDA
4,842.10
3,804.80
3,193.70
930.10

About Proteonomix

View Profile
Address
140 East Ridgewood Avenue
Paramus New Jersey 07652
United States
Employees -
Website mailto:[email protected]
Updated 07/08/2019
Proteonomix, Inc. is a biotechnology company which engages in the discovery and development of stem cell therapeutic and cosmeceutical products. It develops pre clinical-stage therapeutic agents and treatments for diabetes, heart, and lung diseases. Proteonomix was founded by Michael Moshe Cohen on June 26, 1995 and is headquartered in Hawthorne, NJ.